Targeting A549 lung adenocarcinoma cell growth and invasion with protease-activated receptor-1 siRNA

Molecular Medicine Reports

Volumn 9, Issue 5, 2014, Pages 1787-1793

  Wu, Zhuo ^a   Zeng, Yanyan ^b   Zhong, Mingkang ^a   Wang, Bin ^a  

^a FUDAN UNIVERSITY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Lung cancer; Protease activated receptor 1; RNAi; siRNA

Indexed keywords

LIPOFECTAMINE; MESSENGER RNA; PROTEINASE ACTIVATED RECEPTOR 1; SMALL INTERFERING RNA;

ARTICLE; CANCER GROWTH; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; GENETIC TRANSFECTION; LUNG ADENOCARCINOMA; POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; RECEPTOR, PAR-1; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84899508601     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2023     Document Type: Article

References (31)

1. Wang Y, Yang H, Liu H, Huang J and Song X: Effect of staurosporine on the mobility and invasiveness of lung adenocarcinoma A549 cells: an in vitro study. BMC Cancer 9: 174, 2009.
2. Arora P, Ricks TK and Trejo J: Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J Cell Sci 120: 921-928, 2007. (Pubitemid 46638507)
3. 2+ mobilization. FEBS Lett 288: 123-128, 1991.
4. Vu TK, Hung DT, Wheaton VI and Coughlin SR: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64: 1057-1068, 1991. (Pubitemid 121001193)
5. Villares GJ, Zigler M, Wang H, et al: Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res 68: 9078-9086, 2008.
6. Tellez C and Bar-Eli M: Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 22: 3130-3137, 2003. (Pubitemid 36713765)
7. Chay CH, Cooper CR, Gendernalik JD, Dhanasekaran SM, Chinnaiyan AM, Rubin MA, Schmaier AH and Pienta KJ: A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 60: 760-765, 2002. (Pubitemid 35300332)
8. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I and Bar-Shavit R: Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 4: 909-914, 1998. (Pubitemid 28364029)
9. Darmoul D, Gratio V, Devaud H, Lehy T and Laburthe M: Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol 162: 1503-1513, 2003. (Pubitemid 36512832)
10. Zhang Y, Zhan H, Xu W, Yuan Z, Lu P, Zhan L and Li Q: Upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 promotes the progression of human gliomas. Pathol Res Pract 207: 24-29, 2011.
11. Hernández NA, Correa E, Avila EP, Vela TA and Pérez VM: PAR1 is selectively over expressed in high grade breast cancer patients: a cohort study. J Transl Med 7: 47, 2009.
12. Du X, Wang S, Lu J, et al: Correlation between MMP1-PAR1 axis and clinical outcome of primary gallbladder carcinoma. Jpn J Clin Oncol 41: 1086-1093, 2011.
13. Bar-Shavit R, Turm H, Salah Z, Maoz M, Cohen I, Weiss E, Uziely B and Grisaru-Granovsky S: PAR1 plays a role in epithelial malignancies: transcriptional regulation and novel signaling pathway. IUBMB Life 63: 397-402, 2011.
14. Tantivejkul K, Loberg RD, Mawocha SC, Day LL, John LS, Pienta BA, Rubin MA and Pienta KJ: PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem 96: 641-652, 2005. (Pubitemid 41504661)
15. Shimizu S, Gabazza EC, Hayashi T, Ido M, Adachi Y and Suzuki K: Thrombin stimulates the expression of PDGF in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 279: L503-L510, 2000.
16. Huang YQ, Li JJ, Hu L, Lee M and Karpatkin S: Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblasts, DU145 prostate cells and CHRF megakaryocytes. Thromb Haemost 86: 1094-1098, 2001. (Pubitemid 32975838)
17. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A: PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120: 303-313, 2005. (Pubitemid 40222426)
18. Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, Abraham J and Leffall LD: Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med 11: 481-483, 2005. (Pubitemid 40685969)
19. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT and Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 185: 256-261, 1998. (Pubitemid 28320046)
20. Migita T, Sato E, Saito K, Mizoi T, Shiiba K, Matsuno S, Nagura H and Ohtani H: Differing expression of MMPs-1 and -9 and urokinase receptor between diffuse- and intestinal-type gastric carcinoma. Int J Cancer 84: 74-79, 1999. (Pubitemid 29059112)
21. Yang E, Boire A, Agarwal A, Nguyen N, O'Callaghan K, Tu P, Kuliopulos A and Covic L: Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res 69: 6223-6231, 2009.
22. Gartel AL and Kandel ES: RNA interference in cancer. Biomol Eng 23: 17-34, 2006. (Pubitemid 43243836)
23. Kim DH and Rossi JJ: Overview of gene silencing by RNA interference. In: Curr Protoc Nucleic Acid Chem. Beaucage SL (ed). Vol 16. Unit 16.1. Wiley, New York, NY, 2009.
24. Takeshita F and Ochiya T: Therapeutic potential of RNA interference against cancer. Cancer Sci 97: 689-696, 2006. (Pubitemid 43983779)
25. Wu Z, Li X, Zeng Y, Zhuang X, Shen H, Zhu H, Liu H and Xiao H: In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA. Basic Clin Pharmacol Toxicol 108: 177-184, 2011.
26. Xiao H, Wu Z, Shen H, Luo AL, Yang YF, Li XB and Zhu DY: In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi. Basic Clin Pharmacol Toxicol 103: 342-348, 2008.
27. Perrimon N, Ni JQ and Perkins L: In vivo RNAi: today and tomorrow. Cold Spring Harb Perspect Biol 2: a003640, 2010.
28. Seyhan AA: RNAi: a potential new class of therapeutic for human genetic disease. Hum Genet 130: 583-605, 2011.
29. Heller LC, Ugen K and Heller R: Electroporation for targeted gene transfer. Expert Opin Drug Deliv 2: 255-268, 2005. (Pubitemid 41130881)
30. Li S: Electroporation gene therapy: new developments in vivo and in vitro. Curr Gene Ther 4: 309-316, 2004.
31. Wells DJ: Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther 11: 1363-1369, 2004.